An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (Moroctocog Alfa (Af-cc), Recombinant Factor Viii) In Male Chinese Subjects With Hemophilia A
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus First in man; Pharmacokinetics
- Sponsors Pfizer
- 07 Jun 2017 Results published in the Clinical Therapeutics
- 28 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.